Literature DB >> 3600170

Cyclosporine augments reactivity of isolated blood vessels.

F S Lamb, R C Webb.   

Abstract

Administration of cyclosporine (CS) as an immunosuppressive agent in clinical transplantation is associated with multiple side effects including nephrotoxicity and hypertension. These two effects could be related in that the renal changes may be secondary to alterations in organ blood flow. The present studies investigate the ability of CS to augment contractile responsiveness in blood vessels from normotensive rats. Isometric force generation was measured in isolated tail arteries and portal veins. CS (8.3 X 10(-6)M) potentiated tail artery contractile responses to sympathetic nerve stimulation, exogenous norepinephrine, and increases in extracellular potassium concentration. Portal veins undergo spontaneous contractions which are related to the firing of calcium-driven action potentials in the smooth muscle cells. CS significantly increased the frequency of these spontaneous contractile events. These results suggest that components of CS toxicity may involve a direct action on vascular smooth muscle and/or on vascular adrenergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600170     DOI: 10.1016/0024-3205(87)90080-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  17 in total

1.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Coronary vasomotor responses in cyclosporine-treated piglets.

Authors:  G Berkenboom; D Brékine; P Unger; B Gulbis; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

3.  Effect of dietary supplementation with fish oil on cyclosporine A-induced vascular toxicity.

Authors:  G Berkenboom; D Brékine; P Unger; M Richelle; Y Carpentier; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

Review 4.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

5.  Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment.

Authors:  F Cottet-Maire; P V Avdonin; E Roulet; T M Buetler; N Mermod; U T Ruegg
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

6.  AKAP150 contributes to enhanced vascular tone by facilitating large-conductance Ca2+-activated K+ channel remodeling in hyperglycemia and diabetes mellitus.

Authors:  Matthew A Nystoriak; Madeline Nieves-Cintrón; Patrick J Nygren; Simon A Hinke; C Blake Nichols; Chao-Yin Chen; Jose L Puglisi; Leighton T Izu; Donald M Bers; Mark L Dell'acqua; John D Scott; Luis F Santana; Manuel F Navedo
Journal:  Circ Res       Date:  2013-12-09       Impact factor: 17.367

7.  Effect of cyclosporin-A treatment on endotoxin-induced airway hyperreactivity in vivo and in vitro in guinea-pigs.

Authors:  A J Van Oosterhout; F M Woutersen-Van Nijnanten; F P Nijkamp
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

8.  Cellular signaling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide.

Authors:  H Meyer-Lehnert; D Bokemeyer; U Friedrichs; S Drechsler; H J Kramer
Journal:  Clin Investig       Date:  1993-02

9.  Cyclosporine A enhances total cell calcium independent of Na-K-ATPase in vascular smooth muscle cells.

Authors:  D Bokemeyer; U Friedrichs; A Bäcker; H J Kramer; H Meyer-Lehnert
Journal:  Clin Investig       Date:  1994-12

Review 10.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.